NORTH AMERICA AND EUROPE ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) MARKET ANALYSIS

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, by Drug Type (Oral & Parenteral Antibiotics (Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, and Europe) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Nov 2020
Code : CMI4273
Pages :252
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - Regional Analysis

North America is expected to hold dominant position in the North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market. Launch of products by key players is propelling growth of the North America acute bacterial skin and skin structure infections (ABSSSI) market. For instance, in June 2018, Melinta Therapeutics, Inc., a commercial-stage company focused on developing and commercializing novel antibiotics to treat serious bacterial infections, announced the U.S. launch of intravenous and oral formulations of Baxdela (delafloxacin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.

Europe is expected to witness significant growth in the market due to increasing number of product approvals. For instance, in August 2016, Cardiome Pharma Corp. announced that XYDALBA (dalbavancin) has been approved by the European Medicines Agency (EMA) for administration as a single, 30 minute, 1500 mg infusion (three 500mg vials) as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in adults.

Geographies covered: